Vasoactive Peptide Pharmacology

Correct Answer

B — Bosentan

Rationale

Bosentan is classified as a dual ETA and ETB receptor antagonist. Ambrisentan is a selective ETA receptor antagonist. Sildenafil is a phosphodiesterase-5 inhibitor. Riociguat is a soluble guanylate cyclase stimulator. All are used in pulmonary arterial hypertension but belong to distinct pharmacological classes.

Correct Answer

D — Selective ETA receptor antagonist

Rationale

Ambrisentan is classified as a selective ETA receptor antagonist. It blocks the ETA subtype while leaving ETB receptors unoccupied, distinguishing it from bosentan and macitentan, which are both dual ETA and ETB antagonists. By preserving ETB receptor function on vascular endothelial cells, ambrisentan maintains the vasodilatory counter-regulatory response mediated by ETB-driven nitric oxide and prostacyclin release, as well as ETB-mediated clearance of endothelin-1 from the circulation. No approved agent in this class selectively blocks ETB alone.

Correct Answer

A — Dual ETA and ETB receptor antagonist

Rationale

Macitentan is classified as a dual ETA and ETB receptor antagonist, sharing this receptor selectivity profile with bosentan. It was designed for high tissue penetration and sustained receptor occupancy in the pulmonary vasculature. Within the dual-antagonist subclass, macitentan is distinguished by the absence of significant cytochrome P450 enzyme induction and by superior clinical outcome data — the SERAPHIN trial demonstrated a 45 percent reduction in the composite morbidity and mortality endpoint versus placebo. Ambrisentan is the only approved selective ETA antagonist in this class. No agent in the class is a receptor agonist.

Correct Answer

C — Absolutely contraindicated in pregnancy

Rationale

All three endothelin receptor antagonists are classified as absolutely contraindicated in pregnancy. The endothelin system plays a role in fetal cardiovascular and craniofacial development, and blockade during organogenesis causes major congenital defects in animal studies at doses below the human therapeutic range. This is a non-negotiable class label applying to all three agents regardless of their individual receptor selectivity profiles. Cytochrome P450 induction is a property of bosentan only, not shared by ambrisentan or macitentan. Selective ETA antagonism applies only to ambrisentan. Dual ETA and ETB antagonism applies to bosentan and macitentan but not ambrisentan.

Correct Answer

B — CYP3A4 and CYP2C9

Rationale

Bosentan is classified as an inducer of cytochrome P450 3A4 and cytochrome P450 2C9. This enzyme induction property is clinically consequential and distinguishes bosentan from ambrisentan and macitentan, which do not induce cytochrome P450 enzymes. The induction of CYP3A4 and CYP2C9 by bosentan reduces plasma levels of warfarin, statins, hormonal contraceptives, and cyclosporine — all substrates of these pathways. Knowing that bosentan is a CYP3A4 and CYP2C9 inducer is part of the classification vocabulary for this drug within the endothelin receptor antagonist class.

Correct Answer

D — Phosphodiesterase-5 inhibitor

Rationale

Sildenafil is classified as a phosphodiesterase-5 inhibitor. In pulmonary arterial hypertension, phosphodiesterase-5 inhibitors prevent the degradation of cyclic GMP in pulmonary vascular smooth muscle, sustaining the vasodilatory effect of nitric oxide. Current guidelines recommend combining a phosphodiesterase-5 inhibitor such as sildenafil or tadalafil with an endothelin receptor antagonist in most patients with pulmonary arterial hypertension, as the two classes target complementary pathways and produce additive clinical benefit.

Correct Answer

C — They block ETA receptors on pulmonary vascular smooth muscle cells, reducing endothelin-1-driven vasoconstriction and smooth muscle cell proliferation

Rationale

The ETA receptor on vascular smooth muscle cells mediates the dominant pathological effects of endothelin-1 in pulmonary arterial hypertension: sustained vasoconstriction and vascular smooth muscle proliferation leading to medial hypertrophy and luminal narrowing. Blocking ETA receptors reduces both functional vasoconstriction and structural remodeling. Phosphodiesterase-5 inhibition describes sildenafil and tadalafil, not endothelin receptor antagonists. Endothelin receptor antagonists act at the receptor, not at the level of endothelin-1 synthesis. Blocking ETB on endothelial cells would remove the vasodilatory counter-regulatory response — the opposite of what is therapeutically intended.

Correct Answer

A — Dose-dependent transaminase elevation occurs in approximately 10 percent of patients; liver function tests are required at baseline and monthly during therapy and are reversible on dose reduction or discontinuation

Rationale

Bosentan causes dose-dependent liver transaminase elevation in approximately 10 percent of patients. The mechanism involves inhibition of bile salt export pump transporters, leading to intrahepatic bile acid accumulation and hepatocyte injury. Elevations more than three times the upper limit of normal require dose reduction or discontinuation. The transaminase elevations are reversible on stopping the drug. Monthly liver function test monitoring is mandatory for the duration of bosentan therapy. This monitoring requirement distinguishes bosentan from ambrisentan and macitentan, which carry substantially lower hepatotoxicity risk and no longer require routine monthly liver function testing in most regions.

Correct Answer

D — Ambrisentan does not induce cytochrome P450 enzymes, eliminating the induction-based drug interactions and reducing the hepatic metabolic burden associated with bosentan

Rationale

Bosentan induces cytochrome P450 3A4 and 2C9, creating clinically important drug interactions and contributing to hepatic stress. Ambrisentan does not induce these enzymes, giving it a substantially cleaner drug interaction profile. Post-marketing data confirmed that ambrisentan's hepatotoxicity risk is substantially lower than bosentan's, and regulatory agencies in most regions no longer require routine monthly liver function monitoring for ambrisentan. The advantage is pharmacokinetic — the absence of CYP enzyme induction — rather than a pharmacodynamic consequence of ETA selectivity or a difference in renal excretion. Receptor selectivity for ETA is an important pharmacodynamic distinction, but it does not explain the hepatotoxicity and drug interaction differences, which are pharmacokinetic in origin.

Correct Answer

C — Cyclosporine inhibits hepatic uptake transporters, raising bosentan levels and increasing hepatotoxicity risk, while bosentan simultaneously induces cytochrome P450 enzymes and lowers cyclosporine levels

Rationale

The bosentan-cyclosporine interaction is bidirectional and operates through two distinct pharmacokinetic mechanisms. Cyclosporine inhibits organic anion transporting polypeptide transporters responsible for bosentan's hepatic uptake, dramatically raising bosentan plasma levels and markedly increasing hepatotoxicity risk. Simultaneously, bosentan's induction of cytochrome P450 3A4 and 2C9 accelerates cyclosporine metabolism, reducing cyclosporine levels and risking organ rejection. Each drug worsens the other's toxicity-to-efficacy ratio through entirely separate mechanisms. This bidirectional pharmacokinetic interference makes co-administration absolutely contraindicated. The interaction operates through transporter and enzyme pathways, not through receptor competition.

Correct Answer

B — Macitentan reduced the composite endpoint of pulmonary arterial hypertension-related death, hospitalization, or worsening by 45 percent compared to placebo

Rationale

The SERAPHIN trial was the first endothelin receptor antagonist trial powered for morbidity and mortality outcomes rather than exercise capacity alone. It demonstrated that macitentan reduced the composite primary endpoint — pulmonary arterial hypertension-related death, hospitalization, or worsening — by 45 percent relative to placebo. This outcome-based evidence base distinguishes macitentan from earlier trials with bosentan and ambrisentan, which were primarily powered for six-minute walk distance. The 45 percent reduction applies to the composite morbidity and mortality endpoint, not all-cause mortality alone, and the comparison was against placebo rather than another endothelin receptor antagonist.

Correct Answer

D — Bosentan induces cytochrome P450 3A4 and 2C9, accelerating hepatic metabolism of the steroid hormones in oral contraceptives and reducing their plasma levels below the threshold for reliable contraception

Rationale

Bosentan induces cytochrome P450 3A4 and 2C9 — enzymes responsible for metabolizing the steroid hormones in oral contraceptives, including ethinyl estradiol and progestin components. Increased enzyme activity accelerates their hepatic metabolism, lowering plasma hormone levels below the threshold required for reliable contraceptive efficacy. Because of this interaction, hormonal contraceptives including oral pills, patches, and rings cannot be relied upon for contraception in patients on bosentan. Non-hormonal contraception is mandatory. This requirement is additional to the two-method contraception rule applying to all three endothelin receptor antagonists as a class due to teratogenicity.

Correct Answer

A — Stimulation of nitric oxide and prostacyclin release, producing vasodilation as a counter-regulatory response to endothelin-1

Rationale

ETB receptors on vascular endothelial cells stimulate the release of nitric oxide and prostacyclin, both potent vasodilators, producing a counter-regulatory response that partially opposes ETA-mediated vasoconstriction on adjacent smooth muscle. ETB receptors on smooth muscle cells, by contrast, mediate vasoconstriction similarly to ETA receptors. In pulmonary arterial hypertension, the net in vivo effect of elevated endothelin-1 is vasoconstriction because the ETB endothelial vasodilatory response is overwhelmed at the elevated endothelin-1 concentrations present. This dual ETB pharmacology — vasodilatory on endothelium, vasoconstrictive on smooth muscle — is the basis for the theoretical argument that selective ETA antagonism with ambrisentan might preserve the beneficial endothelial ETB vasodilatory and clearance functions.

Correct Answer

B — Pulmonary arteriolar vasoconstriction through ETA receptor activation, smooth muscle cell proliferation causing medial hypertrophy, and fibrosis of the vessel wall

Rationale

Endothelin-1 drives pulmonary vascular disease through three mechanisms operating simultaneously. First, it produces vasoconstriction of the small pulmonary arterioles through ETA receptor activation on smooth muscle cells — the functional, potentially reversible component. Second, it promotes smooth muscle cell proliferation, causing medial hypertrophy and progressive luminal narrowing — the structural remodeling component. Third, it drives fibrosis of the vessel wall, producing fixed structural obstruction. The combination of functional vasoconstriction and fixed structural remodeling explains why endothelin receptor antagonists produce the greatest benefit earlier in the disease course before irreversible structural changes dominate. The cardiac consequences in option A are downstream effects of elevated pulmonary vascular resistance, not direct endothelin-1 mechanisms.

Correct Answer

B — Bosentan inhibits bile salt transport, causing intrahepatic bile acid accumulation and dose-dependent transaminase elevation; the drug should be reduced in dose or discontinued, as elevations are reversible

Rationale

Bosentan causes dose-dependent transaminase elevation through inhibition of bile salt export pump transporters, leading to intrahepatic bile acid accumulation and hepatocyte injury. The elevated aminotransferase here — five times the upper limit of normal — exceeds the threshold of three times the upper limit of normal that requires dose reduction or discontinuation. The transaminase elevations are reversible on dose reduction or stopping the drug. Monthly liver function monitoring in patients on bosentan exists precisely to detect this pattern before it progresses to more severe injury. This is not an immune-mediated or irreversible process, and it is specific to bosentan within the endothelin receptor antagonist class — ambrisentan and macitentan carry substantially lower hepatotoxicity risk and do not require this same monitoring regimen.

Correct Answer

D — Bosentan induces cytochrome P450 2C9, accelerating warfarin metabolism and reducing its anticoagulant effect; switching to ambrisentan or macitentan would avoid this because neither induces cytochrome P450 enzymes

Rationale

Warfarin is metabolized predominantly by cytochrome P450 2C9. Bosentan is a cytochrome P450 2C9 and 3A4 inducer, and when added to a stable warfarin regimen, it accelerates warfarin hepatic metabolism, reducing plasma warfarin levels and lowering the international normalized ratio. In a patient who requires therapeutic anticoagulation — such as this patient with a mechanical valve — an undetected fall in international normalized ratio creates thrombotic risk. The clinical solution is either careful warfarin dose monitoring and adjustment while continuing bosentan, or switching to an endothelin receptor antagonist that does not induce cytochrome P450 enzymes. Ambrisentan and macitentan do not induce cytochrome P450 2C9 or 3A4 and do not produce this drug interaction, making either a safer choice in a patient on warfarin requiring reliable anticoagulation. The mechanism is enzyme induction, not protein binding displacement, absorption inhibition, or vitamin K antagonism.

Correct Answer

A — Bosentan is contraindicated in this patient because cyclosporine inhibits bosentan uptake transporters while bosentan simultaneously lowers cyclosporine levels through cytochrome P450 induction; ambrisentan or macitentan should be used instead

Rationale

Bosentan and cyclosporine interact through two simultaneous pharmacokinetic mechanisms that make the combination absolutely contraindicated. Cyclosporine inhibits organic anion transporting polypeptide transporters responsible for bosentan's hepatic uptake, dramatically raising bosentan levels and increasing hepatotoxicity risk. Simultaneously, bosentan's induction of cytochrome P450 3A4 and 2C9 accelerates cyclosporine metabolism, lowering cyclosporine levels and risking organ rejection. Ambrisentan and macitentan do not induce cytochrome P450 enzymes and do not share this interaction with cyclosporine, making either a suitable choice for this patient. The cyclosporine interaction is specific to bosentan's enzyme induction property and is not a class effect of all endothelin receptor antagonists.

Correct Answer

C — Phosphodiesterase-5 inhibitors

Rationale

Current guidelines recommend combining endothelin receptor antagonists with phosphodiesterase-5 inhibitors — sildenafil or tadalafil — in most patients with pulmonary arterial hypertension. The rationale is mechanistic complementarity: endothelin receptor antagonists block the endothelin-1 pathway, reducing vasoconstriction and smooth muscle proliferation driven by ETA receptor activation. Phosphodiesterase-5 inhibitors act through an entirely separate pathway — they prevent degradation of cyclic GMP in pulmonary vascular smooth muscle, sustaining the vasodilatory effect of nitric oxide. Because the two drug classes act on different vasoactive systems, their combination produces additive reduction in pulmonary vascular resistance beyond what either achieves alone. Angiotensin-converting enzyme inhibitors target the systemic renin-angiotensin-aldosterone system and have no established role in pulmonary arterial hypertension management. Loop diuretics manage volume but do not address the underlying vascular pathology. Beta blockers are generally avoided in pulmonary arterial hypertension.